Thanos Dimopoulos
@thanosdimop
Followers
2K
Following
1K
Media
206
Statuses
2K
Professor of Therapeutics, Hematology, Oncology National and Kapodistrian University of Athens. School of Medicine.
Joined August 2015
RT @VincentRK: The one thing that helped my career was the wisdom of my internal medicine program director who said, you are good, and what….
0
14
0
RT @gsteiris: Ο εορτασμός της Κοιμήσεως της Θεοτόκου στις 15 Αυγούστου καθιερώθηκε από τον βυζαντινό αυτοκράτορα Μαυρίκιο (582-602), όπως μ….
0
14
0
RT @gsteiris: Ω, Εσύ των Ουρανών η πλατυτέρα, που αγκάλιασες τα έθνη & τους λαούς. η θεία Μητέρα, π’ όλους της γης ξεχείλισες τους ναούς.….
0
6
0
RT @AjHematology: Determinants of 15-year progression-free survival in multiple #myeloma; real-world data from a single institution.https:/….
0
10
0
RT @gsteiris: Δεν αντέχεται αυτή η καταστροφή της πατρίδας μας. "Είδα σύναξη πυκνή·κι έξω από τη χώρα ήταν ο τόπος κάψαλο, και σαν απαρνητ….
0
14
0
RT @VincentRK: Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access f….
0
81
0
Myeloma can be cured in some patients and these numbers will increase with current therapist
onlinelibrary.wiley.com
9% of patients with multiple myeloma achieve 15-year progression-free survival; Kaplan-Meier curves for PFS (A) and OS (B).
1
21
70
RT @VincentRK: Shocker for me. ODAC votes against belantamab risk benefit for myeloma. I hope that this vote reflects the way the quest….
0
8
0
RT @Mohty_EBMT: The paper of the day: a landmark publication that is bound to serve as a reference for years to come!.@NatRevClinOncol @….
0
55
0
Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm @EHA_Hematology @EMN_EuMMnet @UoATherapeutics.
nature.com
Nature Reviews Clinical Oncology - In these Evidence-Based Guidelines, a multidisciplinary panel of experts from the European Hematology Association and the European Myeloma Network provide key...
0
29
78
RT @VincentRK: Just out: FDA grants accelerated approval to linvoseltamab for treatment of relapsed/refractory myeloma. It is the 3rd BCM….
ajmc.com
This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.
0
31
0
RT @DrOlaLandgren: FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed/refractory multiple mye….
pharmacytimes.com
The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.
0
10
0
RT @MichalisLiontos: @UoATherapeutics Team at #ESMOGynae25 with our Head @thanosdimop. We presented 3 posters from our clinical researc….
0
5
0
RT @NikhilMunshiMD: Major Regulatory Milestone in MM: In response to an application by I2TEAMM and @IMFmyeloma, the European Medicines Agen….
0
38
0
RT @VincentRK: Breaking: Big news for smoldering myeloma. The Committee for Medicinal Products for Human Use (CHMP) of the European Medic….
0
48
0
Members of the Greek Myeloma Study Group at EHA 2025 At the end of an exciting congress
0
3
23
RT @AuclairDan: Dr. Aurore Perrot updating TRIMM-3 at #EHA2025. Adding an PD-1 to talquetamab promising in potentiating response in patien….
0
8
0
Some members of the Plasma Cell Dyscrasia Unit of Athens at EHA 2025 Milan where we had 11 presentations from our center and 8 in collaboration
0
4
39
Honored to present tomorrow at EHA Milan!Gold Hall at 11 am Sunday June 15 All but one patient responded!Amaizing data which will be the experimental arm of an upcoming randomized study in ND NTE MM patients
0
7
43